The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialAngela Huttner, Claire‐Anne Siegrist, Markus Eickmann et al.|The Lancet Infectious Diseases|2015Cited by 278
Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trialOlga Chatzis, Claire‐Anne Siegrist, Géraldine Blanchard‐Rohner et al.|Clinical Microbiology and Infection|2020Cited by 14
Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 – A Comprehensive AnalysisBenjamin Meyer, Christiane S. Eberhardt, Paola Martinez-Murillo et al.|Frontiers in Immunology|2022Cited by 2